Journal article
Patient perspectives on tapering biologic or targeted synthetic therapy in well-controlled rheumatoid arthritis and comparison with providers' perspectives
Rheumatology (Oxford, England), v 62(Supplement_4), pp IV3-IV7
19 Oct 2023
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective : We examined patient and providers' perspectives on tapering biologic or targeted synthetic disease modifying antirheumatic drugs (bDMARD or tsDMARD) in well-controlled RA to determine which factors influence their long-term treatment decisions.
Methods : A standardized phone survey was administered to patients with well-controlled RA based on electronic health record review. Providers were also surveyed. Univariate and multivariable regression analysis was performed with odds ratios (OR) and 95% CI.
Results : Sixty-two patients and 11 providers completed the survey. In total, 39 (63%) patients would consider a bDMARD/tsDMARD taper. Patients were more likely to consider a taper if they thought their RA was well-controlled (OR 8.02, 95% CI 2.15-29.99, P = 0.002) and of shorter duration (OR 0.94, 95% CI 0.89-0.99, P = 0.02). Patients were less likely to consider a taper if older (OR 0.95, 95% CI 0.91-1.0, P = 0.05), if they were being treated with conventional synthetic DMARDs (OR 0.25, 95% CI 0.07-0.86, P = 0.0275) or daily glucocorticoids (OR 0.08, 95% CI 0.02-0.44, P = 0.0033). Patients' and providers' top concerns about long-term bDMARD/tsDMARD use were malignancy and infection. Their concerns about tapering were worsening pain, flare and loss of function. Patients were more likely to consider a bDMARD/tsDMARD taper than providers (63% vs 36%).
Conclusion : Patients who have had well-controlled RA are more likely to consider tapering bDMARD/tsDMARD when not being treated with csDMARDs or glucocorticoids. Patients and providers shared similar concerns regarding long-term use and tapering of bDMARD/tsDMARD, but patients were more likely to consider a taper.
Metrics
Details
- Title
- Patient perspectives on tapering biologic or targeted synthetic therapy in well-controlled rheumatoid arthritis and comparison with providers' perspectives
- Creators
- Nicholas Wiemer (Corresponding Author) - Allegheny Health NetworkPatrick Webster - Albert Einstein College of MedicineMalavikalakshmi Attur - Drexel UniversityYue Yin - Allegheny-Singer Research InstituteTarun Sharma - Allegheny Health Network
- Publication Details
- Rheumatology (Oxford, England), v 62(Supplement_4), pp IV3-IV7
- Publisher
- Oxford University Press; OXFORD
- Number of pages
- 5
- Grant note
- This work was supported by the Autoimmunity Association Young Investigator Grant Award.
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate); Drexel University
- Web of Science ID
- WOS:001104122700002
- Scopus ID
- 2-s2.0-85175741445
- Other Identifier
- 991021861190704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Rheumatology